These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38799178)

  • 1. Fine excipient materials in carrier-based dry powder inhalation formulations: The interplay of particle size and concentration effects.
    Elsayed MMA; Alfagih IM; Brockbank K; Alheibshy F; Aodah AH; Ali R; Almansour K; Shalash AO
    Int J Pharm X; 2024 Jun; 7():100251. PubMed ID: 38799178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
    Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO
    Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the potential of rheological measurements in development of dry powder inhalation formulations.
    Almansour K; Alfagih IM; Shalash AO; Brockbank K; Ali R; Freeman T; Elsayed MMA
    Int J Pharm; 2022 Feb; 614():121407. PubMed ID: 34942326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J; Ma S; He X; Sun Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2023 Jul; 642():123179. PubMed ID: 37364785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols.
    Muralidharan P; Mallory EK; Malapit M; Phan H; Ledford JG; Hayes D; Mansour HM
    RSC Adv; 2020 Nov; 10(68):41846-41856. PubMed ID: 33391731
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhalable, Spray-Dried Terbinafine Microparticles for Management of Pulmonary Fungal Infections: Optimization of the Excipient Composition and Selection of an Inhalation Device.
    Almansour K; Alfagih IM; Aodah AH; Alheibshy F; Ali R; Al Hagbani T; Elsayed MMA
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.
    Shur J; Harris H; Jones MD; Kaerger JS; Price R
    Pharm Res; 2008 Jul; 25(7):1631-40. PubMed ID: 18239861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
    Sun Y; Yu D; Li J; Zhao J; Feng Y; Zhang X; Mao S
    Eur J Pharm Biopharm; 2022 Oct; 179():47-57. PubMed ID: 36029939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K; Åslund S; Skogevall M; Andersson P
    Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology.
    Tse JY; Kadota K; Imakubo T; Uchiyama H; Tozuka Y
    Eur J Pharm Sci; 2021 Jan; 156():105600. PubMed ID: 33075466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.